États-Unis · Plateformes & données · Morningstar

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

Publié par Morningstar · États-Unis il y a 16 h

Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced Phase 2 results for…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

À lire aussi

Rogers Communications: 3 Key Takeaways for Long-Term Investors

Trump prepares tariff relief on Canada ahead of midterms - report

Think annuities are a rip-off? Now might be the perfect time to reconsider.

Citigroup Forecasts Strong Price Appreciation for Procter & Gamble (NYSE:PG) Stock

Earnings call transcript: Preferred Bank tops Q3 2026 EPS, shares slip premarket

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

Partager

À lire aussi

Rogers Communications: 3 Key Takeaways for Long-Term Investors

Trump prepares tariff relief on Canada ahead of midterms - report

Think annuities are a rip-off? Now might be the perfect time to reconsider.

Citigroup Forecasts Strong Price Appreciation for Procter & Gamble (NYSE:PG) Stock

Earnings call transcript: Preferred Bank tops Q3 2026 EPS, shares slip premarket

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030